Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing ADHD diagnosis rates
3.2.1.2 Advancements in pharmaceutical treatments
3.2.1.3 Increased awareness and education
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of ADHD medications
3.2.2.2 Side effects and concerns with medications
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates & Forecast, By Drug Type, 2021-2032 ($ Mn)
5.1 Key trends
5.2 Stimulants
5.2.1 Amphetamine
5.2.2 Methylphenidate
5.2.3 Lisdexamfetamine
5.2.4 Dexmethylphenidate
5.2.5 Dextroamphetamine
5.3 Non-stimulants
5.3.1 Atomoxetine
5.3.2 Guanfacine
5.3.3 Clonidine
5.3.4 Other non-stimulants
Chapter 6 Market Estimates & Forecast, By Age Group, 2021-2032 ($ Mn)
6.1 Key trends
6.2 Children
6.3 Adults
Chapter 7 Market Estimates & Forecast, By Gender, 2021-2032 ($ Mn)
7.1 Key trends
7.2 Male
7.3 Female
Chapter 8 Market Estimates & Forecast, By Dosage Form, 2021-2032 ($ Mn)
8.1 Key trends
8.2 Tablets
8.3 Capsules
8.4 Other dosage forms
Chapter 9 Market Estimates & Forecast, By Distribution Channel, 2021-2032 ($ Mn)
9.1 Key trends
9.2 Retail pharmacy
9.3 Hospital pharmacy
9.4 Online pharmacy
Chapter 10 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 MEA
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
Chapter 11 Company Profiles
11.1 Aytu BioPharma
11.2 Eli Lilly and Company
11.3 Ironshore
11.4 Janssen Pharmaceuticals
11.5 Lupin
11.6 Mallinckrodt
11.7 Novartis
11.8 Pfizer
11.9 Sun Pharmaceutical
11.10 Supernus Pharmaceutical
11.11 Takeda Pharmaceutical Company
11.12 Teva Pharmaceutical
